Testing effectiveness (Phase 2)Study completedNCT00961064
What this trial is testing
A Pilot Study of a Thrombopoietin-Receptor Agonist, Eltrombopag, in Patients With Low to Int-2 Risk Myelodysplastic Syndrome (MDS)
Who this might be right for
Myelodysplastic SyndromesThrombocytopenia
National Heart, Lung, and Blood Institute (NHLBI) 30